Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-07-30
2000-09-05
Huang, Evelyn Mei
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31454
Patent
active
061143553
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus
patent: 3563986 (1971-02-01), Frankus
patent: 3625946 (1971-12-01), Heinrich et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5405855 (1995-04-01), Andrulis, Jr.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5443824 (1995-08-01), Piacquadio
patent: 5502066 (1996-03-01), Heinemann
patent: 5605684 (1997-02-01), Piacquadio
patent: 5605914 (1997-02-01), Muller
patent: 5643615 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
Algire, G. H., "Vascular Reactions of Normal and Malignant tissues In Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants," J. Nat'l Canc. Inst., pp. 73-85 (1945).
Ambs, S. et al., "Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression", The FASEB Journal, vol. 11, pp. 443-448 (1997).
Apt, W. "Effect of Thalidomide on the Course of Experimental Chagas' Disease", BOI. Chil. Parasitol, vol. 20, No. 3, pp. 84-86 (1965).
Bach, et al., "Studies on the Possible Anti-Neoplastic Effect of Thalidomide", ACTA Pathologica ET Microbiologica Scandinavica, vol. 59, pp. 491-499 (1963).
Bahmer, F.A., "Therapie bel lymphozytischer Infiltration", Der Hautarzt, vol. 43, p. 663 (1992).
Barnes, et al., "Tumor Necrosis Factor Production in Patients with Leprosy", Infection and Immunity, vol. 60, No. 4, pp. 1441-1446 (1992).
Barriere, H., "Traitement par la thalidomide", La Presse Medicale, vol. 12, No. 15, pp. 963 (1983).
Barnhill, R. et al., "Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytres and Monocytes", J. Am. Acad. Derm., vol. 11, No. 5, Part 1, pp. 814-819 (1984).
Bazzoli, et al., "The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt", J. Embryol. exp. Morph., vol. 41, pp. 125-135 (1977).
Beck, Jr. et al. "Vascular Development: Cellular and Molecular Regulation", The FASEB Journal, vol. 11, pp. 365-374 (1997).
Belaube, P. et al., "Should Thalidomide be Rehabilitated?", Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104 (1983).
Bernal, et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", Int'l. J. of Dermat., vol. 31, No. 8, pp. 599-600 (1992).
Blair, R. et al., "Human Mast Cells Stimulate Vascular Tube Formation", Journal of Clinical Investigation, vol. 99, No. 11, pp. 2691-2700 (1997).
Blaschke, V. et al., Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere, Arzneimittel Forsch./Drug Res., vol. 29, No. II, pp. 1640-1642 (1979).
Bonifacino, J. et al., "A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum", Science, vol. 2, pp. 79-80 (1990).
Brem, H. et al., "Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent Gliomas", J. Neurosurg., vol. 74, pp. 441-446 (1991).
Bressler, S. et al., "Clinicopathologic Correlation of Occult Choroidal Neovascularization in Age-Related Macular Degeneration", Arch. Opthalmol., vol. 110, p. 827 (1992).
Buelens, I., Treatment of a Grade II Astrocytoma with Thalidomide (Phthalylglutamic Acid Imide) [Behandlung eines Astrocytoms II. Grades mit Thaliodmid (N-Phthalylglutaminsaureimid)], Arzneim.-Forsch., vol. 17, No. 5, pp. 646-648 (1967).
Burrows, N.P., "Thalidomide Modifies Disease", Brit. Med. J., vol. 307, No. 6909, pp. 939-940 (1993).
Browne, M.J. et al., Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells, Fibrinolysis, vol. 5, pp. 257-260 (1991).
Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", J. of the Royal Soc. of Med., vol. 83, pp. 590-591 (1990).
Cashin, C.H. et al., "Angiogenesis and Chronic Inflammation", Agents and Actions, vol. 34, No. 3/4, pp. 332-338 (1991).
Casini, G. et al., "Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimmidoglutarimmide", Il Pharmaco, Ed. Sc., vol. XIX, Fasc. 6, pp. 563-565 (1964).
Chaudhry, A. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in Hampsters", Canc. Res., vol. 26, No. 9, Part 1, pp. 1884-1886 (1966).
Chen, T. et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy Male Volunteers", The Am. Society for Pharma. and Experi. Therapeutics, vol. 17, No. 4, pp. 402-405 (1988).
Colville-Nash, P.R. et al., "Angiogenesis and rheumatoid arthritis: Pathogenic and Therapeutic Implications", Ann. Rheum. Dis., vol. 51, pp. 919-925 (1992).
Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", J. of Autoimmunity, vol. 2, pp. 197-202 (1989).
Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment", Science, vol. 230, pp. 1375-1378 (1985).
D'Amato, R. J. et al., "Thalidomide is an Inhibitor of Angiogenesis", Proc. Natl. Acad. Sci., vol. 91, pp. 4082-4085 (1994).
De, A.U. et al., "Possible Antineoplastic Agents I", J. of Pharma. Sci., vol. 64, No. 2, pp. 262-266 (1975).
De Cock, K., "Treatment of Ulcerative Colitis", Brit. Med. J., vol. 1, pp. 1356 (1979).
Dicken, C. H., "Malignant pyoderma", J. of the Am. Acad. of Dermatol., vol. 13, No. 6, pp. 1021-1025 (1985).
Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide", Arzheim. Forsch/Drug Res., vol. 40 (II), No. 10, pp. 1073-1075 (1990).
Ehrlich, G.E., "Behcet's Disease: Current Concepts", Comprehensive Therapy, vol. 15, No. 1, pp. 27-30 (1989).
Eisenbud, L. et al., "Recurrent Aphthous Stomatitis of the Behcet's Type: Successful Treatment with Thalidomide", Oral Surgery, Oral Medicine, Oral Pathology, vol. 64, No. 3, pp. 289-292 (1987).
Eravelly, J. et al., "Thalidomide in Weber-Christian Disease", The Lancet, vol. 1, No. 8005, p. 251 (1977).
Eriksson, S. O. et al., "Synthesis and Alkaline Hydrolysis of Some N-substituted Phthalimides", Acta Pharm. Suecica, vol. 10, pp. 63-74 (1973).
Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites", Brit. J. Pharmacol.,vol. 25, pp. 352-362 (1965).
Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds", Life Sci., vol. 3, pp. 987-992 (1964).
Fabro, S. M.D., "Biochemical Basis of Thalidomide Teratogenicity", The Biochemical Basis of Chemical Teratogenesis, Chapter 5, pp. 159-178 (1981).
Fazal, N. et al., "Effect of Blocking TNF-.alpha. on Intracellular BCG (Bacillus Calmette Guerin) Growth in Human Monocyte-Derived Macrophages", FEMS Microbiology Immunology, vol. 105, pp. 337-346 (1992).
Fickentscher, K. et al., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides", Mol. Pharmacol., vol. 13, pp. 133-141 (1977).
Field, E. O. et al., "Effect of Thalidomide on Splenomegaly (GVH Reaction) in the Chick Embryo. Treatment of Donor Cells Only", Nature, vol. 211, No. 5055, pp. 1309-1310 (1966).
Flohe, L. et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis", Arzneimitte/Forschung (Germany West), vol. 31, No. 2, pp. 315-320 (1981).
Folkman, J. et al., "Angiogenesis", J. Biol. Chem., vol. 267, No. 16, pp. 10931-10934 (1992).
Folkman, J. et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Prese
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212474